THERE IS EVIDENCE OF INCREASED RISK OF CANCER IN PATIENTS USING HUMAN INSULIN ANALOGUE GLARGINE FOR TREATMENT OF DIABETES MELLITUS - OVERVIEW BASED EVALUATION
Author(s)
Alvares J1, Izidoro JB1, Moreira DP1, Diniz LM2, Guerra-Júnior AA1, Acurcio Fd1
1College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Medical College, Federal University of Minas Gerais, Belo Horizonte, Brazil
OBJECTIVES: The use of Glargine for the treatment of diabetes mellitus has been widespread, but recently generated concerns about the safety related to a supposed increased risk of cancer by its use. The aim of this study was to evaluate the safety of Glargine preparations in the treatment of diabetes compared to any other therapeutic options. METHODS: We examined the databases “The Cochrane Library” (via Bireme), Medline (via PubMed) and EMBASE (accessed December/2014). We sought to systematic reviews, cohort studies, case-control studies and randomized clinical trials that evaluated the association between the occurrence of any type of cancer and the use of Glargine. Also searched for health technology assessments on websites of international agencies and of the Brazilian Network for Health Technology Assessment. The quality evaluation of the studies was performed according to the GRADE system for systematic reviews, Newcastle-Ottawa scale for cohort and case-control studies and Jadad modified scale for clinical trials. RESULTS: Eleven studies were included, 3 systematic reviews , 4 cohorts, 3 case-control and a randomized clinical trial. The studies showed good methodological quality ratings. There is no statistically significant results to associate the overall development of cancer among patients who used Glargine compared with patients treated with human insulin or oral antidiabetic therapy. The data with respect to specific types of cancer also presented inconclusive evidence. We didn´t found health technology assessments of international agencies on the subject, only warnings about a possible association therapy with Glargine analog with cancer. CONCLUSIONS: Based on the available scientific evidence there is no clear relationship between the use of Glargine and cancer development. It´s use has apparently similar safety profile as of the therapeutic alternatives available. Therefore, is not recommended discontinuation of therapy with Glargine for security reasons related to the occurrence of cancer.
Conference/Value in Health Info
2015-09, ISPOR Latin America 2015, Santiago, Chile
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PDB6
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Diabetes/Endocrine/Metabolic Disorders